We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

CASI Pharmaceuticals Inc (CASI) USD0.0001

Sell:$2.20 Buy:$3.10 Change: $0.11 (4.12%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$2.20
Buy:$3.10
Change: $0.11 (4.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$2.20
Buy:$3.10
Change: $0.11 (4.12%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Contact details

Address:
1701-1702, China Central Office Tower 1,
BEIJING
100025
China
Telephone:
+86 () 1065618789
Website:
www.casipharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CASI
ISIN:
KYG1933S1012
Market cap:
$35.50 million
Shares in issue:
13.40 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wei-Wu He
    Chairman of the Board, Chief Executive Officer
  • Wei Zhang
    President, Principal Financial Officer
  • Chunhua Wang
    Chief Operating Officer
  • Huang Hai
    Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
  • Alexander Zukiwski
    Executive Vice President, Chief Medical Officer
  • Kun Qian
    Vice President, Controller
  • Wei Gao
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.